More evidence for unprotected left main PCI

Original title: Outcomes After Emergency Percutaneous Coronary Intervention in Patients UIT unprotected Left Main Stem Occlusion. The BCIS National Audit of Percutaneous Coronary Intervention 6-Years Experience. Reference: Niket Patel, et al. J Am Coll Cardiol Interv 2014;7:969-80

AMI involving unprotected left main is not frequent in catheterization labs since most of these cases present in shock. There is little information in the literature and follow up is scarce. Between January 2007 and December 2012 a total of 446,257 PCI procedures were registered at the British Cardiovascular Intervention Society.

All patients registered to primary PCI were analyzed; 568 of these patients presented unprotected left main stem occlusion, 1,045 presented non occlusive lesion and 97,974 had no left main compromise. 

Those with left main lesion were older, often women, diabetic and presented renal failure. The unprotected left main stem occlusion group presented reduced ejection fraction and cardiogenic shock. Time intervals from symptom onset to hospitalization and symptom onset to balloon were lower for those with left main occlusion. 

Femoral access, multi vessel PCI, mechanical respiratory assistance, pump support and hospitalization time were more frequent in the left main PCI group.  At hospital level, mortality was 6 times higher for those with left main lesion (26.4% vs 4.1% <0.001) and it was even higher in patients with left main occlusion vs. patients with non-occlusive lesions (43.3% vs. 20.6% <0.001).

Follow up at 1 and 3 years, mortality was higher in patients with left main compromise (39.8% and 60.4% vs. 9.8% and 20.7% respectively; p <0.001). 

Conclusion

Unprotected left main primary PCI outcomes are often poor and require additional therapies to be improved. However, long term outcomes in survivors are encouraging.

Commentary

Unprotected left main primary PCI is one of the worst scenarios we could face. It requires vast experience and fast action, with outcomes that are not auspicious. It is necessary to develop support circulatory systems as well as new drugs or strategies to obtain better results.

Corrtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation
Buenos Aires- Argentina

Carlos Fava

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...